- Trial phase
- Approved
- Time to market
- Already approved and commercially available since March 2023.
- Why 4/10
- APONVIE is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst is the closing of the CorMedix asset acquisition (expected Q1 2027), which is an M&A event, not a drug-specific binary catalyst. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
APONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.
Price Chart
Executive Summary
APONVIE (aprepitant injectable emulsion) is an FDA-approved intravenous treatment for postoperative nausea and vomiting (PONV), developed by Heron Therapeutics (HRTX). Approved in September 2022 and commercially launched in March 2023, it is the first and only IV formulation of an NK1 receptor antagonist for PONV, delivered as a single 30-second injection. APONVIE revenue grew 49.3% YoY in Q3 2026, but on November 9, 2026, Heron announced it would sell substantially all assets -- including APONVIE -- to CorMedix Therapeutics (CRMD) for approximately $223M upfront plus earn-outs, with the deal expected to close in Q1 2027. For Heron shareholders, APONVIE's future economics are now tied to the CorMedix transaction rather than standalone commercial execution.
How It Works
APONVIE is an intravenous (IV) injectable emulsion of aprepitant, which blocks the neurokinin-1 (NK1) receptor in the brain that triggers nausea and vomiting. It is given as a single 30-second IV injection before surgery and provides 48 hours of protection against postoperative nausea and vomiting (PONV). Unlike oral anti-nausea pills, the IV formulation works quickly and is suitable for patients who cannot take oral medications after surgery.
Trial Status
APONVIE was FDA-approved on September 16, 2022, based on clinical trials demonstrating efficacy for prevention of postoperative nausea and vomiting. It was commercially launched in the U.S. in March 2023 and has since been included in the Fifth Consensus Guidelines for PONV management (December 2025).
The Two-Sided Case
Upcoming Catalysts
- Closing of CorMedix asset acquisition, expected Q1 2027 (the deal was announced November 9, 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HERON THERAPEUTICS, INC. /DE/ DEFA14A HRTX ·Originating report